Cancer Network
Spotlight
Acute Lymphoblastic LeukemiaAround the PracticeASCO Genitourinary Cancers SymposiumHER2-Positive Breast CancerNon-Small Cell Lung Cancer (NSCLC)Prostate Cancer
Clinical
View MoreBrain CancerBreast CancerColorectal CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer
News
All NewsNP/PAPractice ManagementTechnology
Media
Around the PracticeClinical ConsultEnduring WebinarsExpert InterviewsK-CastMedical World NewsPodcastsReadout 360Tumor Board Series
Conferences
Publications
About Oncology JournalOncology Journal
Events
Live EventsVirtual Events
CME/CE
Resources
Image IQPollsQuizzesSlideshowsSponsoredToolkits
Subscribe
eNewsletterPrint Subscription

  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Cancer Network. All rights reserved.

Spotlight
  • Acute Lymphoblastic Leukemia
  • Around the Practice
  • ASCO Genitourinary Cancers Symposium
  • HER2-Positive Breast Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Prostate Cancer
ClinicalSee All >
  • Brain Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Gynecologic Cancer
  • Hematology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Pediatric Cancers
  • Skin Cancer
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.

Kevin Kalinsky, MD, MS, on Next Steps Following the Phase 3 RxPONDER Trial

January 20, 2021
Kristie L. Kahl
Kristie L. Kahl

Investigators aimed to evaluate additional end points from the phase 3 RxPONDER trial in women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer.

Following results that were reported at the 2020 San Antonio Breast Cancer Symposium, investigators of the phase 3 RxPONDER trial (NCT01272037) hope to further evaluate the clinical benefit from the addition of chemotherapy to endocrine therapy in women with hormone receptor (HR)–positive, HER2-negative, lymph node–positive breast cancer and an Oncotype DX Recurrence Score between 0 and 25.

Kevin Kalinsky, MD, MS, acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine as well as director of both the Glenn Family Breast Center and of breast medical oncology at Winship Cancer Institute of Emory University, spoke with CancerNetwork® about next steps following the phase 3 RxPONDER trial.

Transcription:

I have a lot of work to do. We were only reporting at about 50% of the events, so we’re still awaiting additional events. And we’ll put this out as data come. We’ll also be reporting things like quality-of-life outcomes and other end points. And then there’s also a translational medicine component to this where we’ve collected primary tissue and lymph nodes involved that weren’t involved, in the hopes that we could also look at additional predictors or prognostic signatures that can help inform this patient population and potentially future studies as well.

Related Content:

SABCSBreast CancerConference
Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 Study

Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010

Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010